9Y4 Stock Overview
A clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Ryvu Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł9.96 |
| 52 Week High | zł15.32 |
| 52 Week Low | zł8.90 |
| Beta | 0.65 |
| 11 Month Change | -9.45% |
| 3 Month Change | -15.16% |
| 1 Year Change | -23.85% |
| 33 Year Change | -21.82% |
| 5 Year Change | n/a |
| Change since IPO | -7.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9Y4 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.9% | 3.9% | 0.8% |
| 1Y | -23.9% | 5.4% | 9.1% |
Return vs Industry: 9Y4 underperformed the German Life Sciences industry which returned 3.6% over the past year.
Return vs Market: 9Y4 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| 9Y4 volatility | |
|---|---|
| 9Y4 Average Weekly Movement | 6.3% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9Y4 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 9Y4's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 270 | Pawel Przewiezlikowski | ryvu.com |
Ryvu Therapeutics S.A., a clinical-stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company’s products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia.
Ryvu Therapeutics S.A. Fundamentals Summary
| 9Y4 fundamental statistics | |
|---|---|
| Market cap | €241.43m |
| Earnings (TTM) | -€24.17m |
| Revenue (TTM) | €21.16m |
11.4x
P/S Ratio-10.0x
P/E RatioIs 9Y4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9Y4 income statement (TTM) | |
|---|---|
| Revenue | zł91.18m |
| Cost of Revenue | zł18.68m |
| Gross Profit | zł72.50m |
| Other Expenses | zł176.63m |
| Earnings | -zł104.14m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.50 |
| Gross Margin | 79.51% |
| Net Profit Margin | -114.21% |
| Debt/Equity Ratio | 45.3% |
How did 9Y4 perform over the long term?
See historical performance and comparison